Drug
Eplontersen
Eplontersen: highest development phase Phase 3, developed by AstraZeneca, Ionis Pharmaceuticals. 3 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- AstraZeneca, Ionis Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| Eplontersen NCT06194825 | Phase 3 | Transthyretin Amyloid Cardiomyopathy |
| Eplontersen NCT05667493 | Phase 3 | Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) |
| Eplontersen NCT04136171 | Phase 3 | Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) |
Latest
No recent events.
Follow Eplontersen on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.